Eli Lilly and Company $LLY Shares Bought by Moneta Group Investment Advisors LLC

Moneta Group Investment Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 16.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,493 shares of the company’s stock after purchasing an additional 2,033 shares during the quarter. Moneta Group Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $11,058,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the second quarter worth approximately $29,000. Steph & Co. increased its position in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares in the last quarter. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $31,000. Finally, Bare Financial Services Inc raised its stake in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $987.83 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company has a market capitalization of $933.32 billion, a price-to-earnings ratio of 43.04, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The firm’s fifty day moving average price is $1,036.20 and its 200 day moving average price is $954.12.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the company posted $5.32 EPS. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Top analysts reiterated bullish ratings and raised targets for LLY, citing continued GLP‑1 growth and the launch of Employer Connect to broaden access to obesity medicines — supporting upside expectations. Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans
• Positive Sentiment: Positive topline Phase 3 pediatric results for EBGLYSS (lebrikizumab) showed meaningful skin clearance and itch relief in children 6 months–18 years, supporting potential label expansion and strengthening Lilly’s immunology growth story. Lilly’s EBGLYSS is first selective IL-13 inhibitor with positive Phase 3 pediatric outcomes
• Positive Sentiment: Management is expanding manufacturing and market reach (including plans to invest in China) to support rollout of orforglipron and other GLP‑1 products, which investors view as capacity/readiness positives for future revenue. Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports
• Neutral Sentiment: A congressional purchase of LLY was disclosed (standard 45‑day lag); such filings can draw attention but are typically not a fresh driver for price moves once public. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: New rival oral GLP‑1 candidates are posting strong mid‑stage weight‑loss results (Structure Therapeutics and others), raising competitive risk that could pressure Lilly’s market share or pricing over time. Structure Weight-Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Investor commentary warns valuation already reflects a lot of GLP‑1 upside, suggesting limited near‑term upside and greater sensitivity to any negative news or weaker growth execution. Is There Too Much Bullishness Priced Into Eli Lilly’s Stock Price?

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. HSBC restated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 10th. The Goldman Sachs Group set a $1,260.00 price objective on Eli Lilly and Company in a research report on Thursday, February 5th. Daiwa Securities Group boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Argus upped their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Guggenheim increased their target price on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.